Bioanalytical Complex Assay Development - Mini Podcast Biosimilar Development Capabilities – Watch Now Vaccine Development Capabilities - Brochure Check out our latest Validated PK & ADA Methods List Read about Veeda's partnership with Ahammune Biosciences for first in human studies Watch our Latest Symposium on Immuno-centric Approach to Biosimilar and Vaccine Development Check out our Assay List (Method Library)
Pre Clinical Research and Development
Drug Chemistry & Preclinial Services
Bioavailability & Bioequivalence (BA/BE)
BA/BE Studies in Healthy Volunteers
BA/BE Studies in Patients
Complex Generics
Bio Analytical
Small molecule PK analysis
Central laboratory services
Specialized LC/MS/MS analysis support
Assay List
Early phase Clinical Development
Phase 1 Unit Overview
Phase 1 studies on IMPs/NCEs
Experimental Medicine Study (IES) Capabilities
Phase 1 study Experience
Phase 1 Study in Patients
Late Phase Clinical Development
Phase II to Phase IV clinical trials
Late Phase trials-Technologies
Bio-Pharmaceutics & Data Science
Bio-pharmaceutics Services
Statistical Services
Clinical Data Management (CDM) Services
Biologics & Biosimilars
Large Molecule Bioanalysis
Biosimilar Bioanalysis
PK/ADA Assay List
Pharmacovigilance Services
Safety Database -VINCURA
Regulatory Services Overview
Regulatory timelines process & regulation FAQs
Veeda's Events
Life at Veeda
Working at Veeda
Veeda Insights
Shareholder's Information
Material Contracts and Documents for Inspection
Veeda Clinical Research, has set foot in the preclinical ecosystem by acquiring a majority stake in Bioneeds (a reputed Preclinical CRO with more than 12 years of experience). Veeda will now provide full service as well as functional service in all the stages of drug development to support biotech and pharmaceutical companies.
With the acquisition of Bioneeds, Veeda Clinical Research has now the capability to support (bio)pharmaceutical companies with their preclinical studies towards IND and NDA submission of both oncology and non-oncology NCE/NME. The acquisition marks a significant moment in Veeda CR's history as it accelerates Veeda's transformation journey and its commitment to be a 360 degree service provider in innovation and delivery of novel drugs.
Bioneeds - A Leading Preclinical Contract Research Organization
One stop solution for services related to preclinical studies in drug development
Rich experience in conducting preclinical studies
GLP certified test facility and accredited by the AAALAC International (The Association for Assessment and Accreditation of Laboratory Animal Care International)
Product characterization - HPLC (ProA, RP, SE, CE), LC-MS (ORBITRAP) - Intact mass, subunit analysis, peptide mapping, disulfide bond locations, glycan analysis cell/ELISA based assays, BIACORE based assays
Rich experience in medicinal chemistry, custom synthesis, process R&D and scale-up
Drug Chemistry & Preclinical Services
Exploratory studies: Dose limiting toxicology studies & dose escalation toxicology studies
IND enabling safety studies across mammalian toxicology, genetic toxicology, DMPK, and bio-analysis
Impurity qualification studies (Profiling, isolation, characterization, certification and evaluation)
Toxicokinetic analysis
Preclinical bioanalytical services (Method development & validation)
Immunogenicity testing
Bioassays (In vitro/In vivo)
Cell based potency & functional assays
Portfolio of ADMET assays for NDA/ANDA enabling safety evaluations
Polyclonal and monoclonal antibody development and purification
Product characterization and product release testing for biopharmaceuticals
In vitro studies that are alternative to in vivo studies
Synthesis of potential metabolites & impurities for initial studies
Why Veeda?
Veeda is an independent indian CRO with 16 years of experience
Veeda has conducted over 3800+ studies & has worked with over 200 (Bio)pharmaceutical companies around the world
Veeda has an exemplary regulatory record of successfully completing audits of USFDA, AGES, MHRA, ANVISA, WHO, NPA, ANSM, MCC, DCGI & NPRA
Due to stringent quality norms and transparency at all stages, Veeda is considered to be a preferred partner for many (Bio)pharmaceutical companies
Veeda's has a vast experience in scientific and regulatory compliant protocol designing that enables the drug development process of Early to Late phase clinical trials
Veeda has over 900+ analytical methods & 60+ NCE molecules developed and validated so far
Veeda ensures study specific clinical safety measures for all subjects through risk mitigation strategies
Veeda has Quality Management System in place to capture any non-compliance or deviation identified during the study with an effective mechanism of corrective and preventive actions implemented
Submit your details and we'll be in touch shortly. You can also email us if you would prefer.
---Pre Clinical Research and DevelopmentBioavailability & Bioequivalence (BA/BE)Bio AnalyticalEarly phase Clinical DevelopmentLate phase Clinical DevelopmentBio-Pharmaceutics & Data ScienceBiologics & BiosimilarsPharmacovigilanceRegulatoryOthers
Veeda Clinical Research Limited (Previously known as Veeda Clinical Research Private Limited) is one of the largest independent Clinical Research Organization established in India in the year 2004 with a vision of creating a CRO with an in-depth scientific know-how, technical edge and better foresight for critical product development programs of innovative global Bio(pharmaceutical) companies
Veeda Clinical Research Limited
(Previously known as
Veeda Clinical Research Private Limited)
6, Magnet Corporate Park,
100 ft. Thaltej - Hebatpur Road,
Nr.Sola Bridge, Off. S.G.
Highway,
Thaltej, Ahmedabad 380 054
info@veedacr.com
© Copyright 2022 Veeda Clinical Research, All Rights Reserved.
Schedule a Meeting with our team today!
---Pre Clinical Research and DevelopmentBioavailability & Bioequivalence (BA/BE)Bio AnalyticalEarly phase Clinical DevelopmentLate phase Clinical DevelopmentBio- Pharmaceutics & Data ScienceBiologics & BiosimilarsPharmacovigilanceRegulatoryOthers
Pharma Synergy 2023DCAT Week 2023
Ajay Tandon, Managing Director
Prior to joining Veeda Clinical Research in May 2019, Mr Tandon was Partner-Operations with CX Advisors LLC, an India mid-market focused private equity investment advisor, where he worked with portfolio companies in developing and enabling strategic initiatives and performance improvements and supporting operational due diligence of target investments. Prior to CX, Mr. Tandon was a Managing Director with The Rohatyn Group and a Director with CVCI, prior to its acquisition by The Rohatyn Group. During the eight years he worked there Mr. Tandon identified, managed and exited a large number of companies across a wide spectrum of industries including, among others, automotive, financial services, IT, IT enabled services, infrastructure, oil & gas services and mining. Prior to CVCI, Mr. Tandon gained 15 years of banking experience with Citibank during which he managed and advised several mid and large corporate clients across diverse industries. Mr. Tandon earned an MBA from the Indian Institute of Management, Ahmedabad and a B.Engineering (Honours) degree in Electrical Engineering from Delhi College of Engineering, Delhi University.
Aparajita Jethy Ahuja, Director
Prior to joining the Investment Advisor in 2009, Ms. Ahuja served in the Funds Administration team at Actis where she was responsible for investor relations and reporting, accounting and compliance. Ms. Ahuja began her career in the Assurance division of Ernst & Young. Ms. Ahuja is a qualified Chartered Accountant (2006) and has a B.Com. (Honours) degree from Delhi University (2003).
Apurva Shah, Founder & Director
Mr. Apurva Shah is a founder and Director of Veeda Clinical Research. He has a MBA in International Finance & Entrepreneurship from Babson College in Boston USA. With his strong entrepreneurial and organizational skills, he has been able to grow Veeda to become one of the premier CROs in the country. As a Board member, he gives strategic and financial direction to all Group Companies. Mr. Shah strongly believes in giving back to the society and hence as a Managing Committee member of the NGO 'Each One Teach One' (www.eotoindia.org) he helps in furthering the cause of education and development of under privileged children in cities and tribal areas. During his tenure as the Chairman of Association of CROs in India (www.acroindia.org) from 2010-2014, he was able to grow the association membership 5 fold, increase the awareness of the industry and work with the Regulatory Agencies to facilitate the growth of the industry. He believes that if done in an ethical manner, clinical research is a very attractive socio-economic opportunity for India. He is on the Governing Board of the Life Science Sector Skill Development Council (www.lsssdc.in) set up by the Government of India. He has also been a member of the Pharma committee of CII for the past 5 years. Mr. Apurva Shah and Mr. Binoy Gardi were awarded the prestigious Entrepreneur of the year in 2009 by the BioSpectrum magazine as recognition for his contribution to the industry and were awarded the SME Entrepreneur of the year by Business Today and Yes Bank in 2010.
Binoy Gardi, Founder & Director
Mr. Binoy Gardi is a founder and Director of Veeda Clinical Research. Mr. Gardi is responsible for strategic planning, developing and implementing new services and establishing relationships with the firm's growing client base. His entrepreneurial vision has led the Company to become one of the fastest growing CROs in India. Mr. Gardi also spends part of his time pursuing his philanthropic ventures. He is responsible for setting up and running two 500 bed hospitals in India. Both hospitals offer free healthcare and medicines. He is one of the main Trustees of RD Gardi Medical College which has now 150 seats and a total of 850 students for MBBS and post graduate courses. Mr Gardi is also Managing Trustee of Shri Bharat Saraswati Mandir Sansad Trust, this is one of the oldest trusts in Gujarat and has 16 educational units with over 3000 students. Mr. Gardi has won the Entrepreneur of the year in 2009 by BioSpectrum magazine and was awarded the SME entrepreneur of the year by BUSINESS TODAY and YES BANK in 2010. Mr. Gardi has a BSc in Business Management from Kings College London and is also a qualified lawyer from the UK. He has also received a diploma from London Business School in Investment Management.